Результаты исследований: Научные публикации в периодических изданиях › Обзорная статья › Рецензирование
NK-cells as innate immunity elements manifest key reactions of antitumor immune response. NKG2D is an activating transmembrane receptor of NK-cells which is responsible for cytotoxicity initiation in response to the binding of specific ligands of genetically modified cells. Selective expression of NKG2D ligands provides a unique perspective on the therapy of wide variety of tumors. Acute myeloid leukemias (AML) are malignant hematological tumors with a high relapse risk. Due to the complexity of AML treatment strategy it is necessary to develop new approaches to tumor elimination using novel genetic constructs. Currently available CAR T-cell drugs with NKG2D receptor are successfully subjected to clinical studies in AML patients and prove their high therapeutic potential.
Переведенное название | CAR T-cell therapy with NKG2D chimeric antigen receptor in relapsed/ refractory acute myeloid leukemia and myelodysplastic syndrome |
---|---|
Язык оригинала | русский |
Страницы (с-по) | 138-148 |
Число страниц | 11 |
Журнал | Klinicheskaya Onkogematologiya/Clinical Oncohematology |
Том | 14 |
Номер выпуска | 1 |
DOI | |
Состояние | Опубликовано - 2021 |
ID: 84919741